Altre lingue Editas Medicine, Inc.

Azioni

EDIT

US28106W1036

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
5,22 ^USD	-2,43%		-5,95%	-48,47%

13/03	Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
29/02	EDITAS MEDICINE, INC. : per Barclays il titolo è Neutral	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting	22/04
Editas Medicine : April 2024 Corporate Presentation	12/04
Editas Medicine : Corporate Effectiveness Report April 2024	12/04
Editas: Q4 Earnings Snapshot	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02
North American Morning Briefing : Stock Futures -2-	21/02
Editas Medicine to Participate in Upcoming Investor Conferences	31/01
Editas Medicine to Participate in Upcoming Investor Conferences	31/01
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	08/01
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	08/01
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update	13/12
Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9	13/12
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals	13/12
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9	13/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Editas Medicine, Inc.

Azioni

EDIT

US28106W1036

Altre lingue

Filtri